罗格列酮对2型糖尿病肥胖病人颈动脉内膜中层厚度及斑块的影响  

Effects of Rosiglitazone on Carotid Intima-Media Thickness and Plaque in Patients with Type 2 Diabetes Mellitus

作　　者：张鸿飞[1] 肖立中[2] 林晓云[1] 江志平[2] 

机构地区：[1]广东省韶关大学医院 [2]广东省粤北人民医院

出　　处：《中西医结合心脑血管病杂志》2005年第12期1055-1057,共3页Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease

摘　　要：目的应用超声评价2型糖尿病病人经罗格列酮长期治疗后颈动脉内膜中层厚度(IMT)及斑块的变化。方法选择59例2型糖尿病伴肥胖病人,随机分成对照组(29例)与治疗组(30例),治疗组加用罗格列酮治疗24个月,治疗前后应用高频超声检测IMT及斑块变化,同时测定血清一氧化氮(NO)、C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)。结果与对照组比较,治疗组IMT及斑块检出率降低(P<0.01或P<0.05),血清NO增加,CRP、TNF-α降低(P<0.01)。与治疗前比较,对照组IMT增加(P<0.01),斑块检出率及血清NO、CRP、TNF-α无明显变化(P>0.05)。结论罗格列酮长期治疗能延缓2型糖尿病病人颈动脉粥样硬化进展,稳定斑块。Objective To investigate the effects of rosiglitazone on carotid intimamedia thickness（IMT） and arterial plaque in patients （pts） with type 2 diabetes mellitus（DM） by carotid ultrasonography. Methods Fifty - nine pts with obese DM were divided into two groups randomly：Pts in control group （ n = 29） received routine therapy, and pts in treatment group （n = 30） received rosiglitazone with routine therapy for 24 months, Carotid IMT and arterial plaque were measured by carotid ultrasonography pre - and post - therapy. The level of serum nitric oxide （NO）, C - reactive protein （CRP） and tumor necrosis factor - α （ TNF - α） were assayed. Results Compared with control group, The IMT and percentage of carotid arterial plaque were decreased following rosiglitazone therapy （P〈 0.01 and 0.05）. Serum NO, CRP and TNF -α decreased （P〈0.01）. Compared with pretherapy, IMT in control group increased （P 〈 0.01 ）. No significant change were found in carotid arterial plaque and serum level of NO, CRP and TNF- α （P 〉0.05）. Conclusion Rosiglitazone could retard atherosclerosis progression and stabilize arterial plaque in obese patients with type 2 DM.

关 键 词：2型糖尿病 动脉粥样硬化 超声 内膜中层厚度 罗格列酮 

分 类 号：R587.1[医药卫生—内分泌] R255.4[医药卫生—内科学]